Arctigenin Inhibits Liver Cancer Tumorigenesis by Inhibiting Gankyrin Expression via C/EBPα and PPARα
- Published: 01 Mar 2018 Journal: Frontiers in Pharmacology (issn: 1663-9812,
Copyright policy)
- Publisher: Frontiers Media S.A.
Bajaj M.Suraamornkul S.Hardies L. J.Glass L.Musi N.DeFronzo R. A. (2007). Effects of peroxisome proliferator-activated receptor (PPAR)-α and PPAR-γ agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus. Diabetologia 50 1723–1731. 10.1007/s00125-007-0698-9 17520238 [OpenAIRE] [PubMed] [DOI]
Balanarasimha M.Davis A. M.Soman F. L.Rider S. D.Jr.Hostetler H. A. (2014). Ligand-regulated heterodimerization of peroxisome proliferator-activated receptor α with liver X receptor α. Biochemistry 53 2632–2643. 10.1021/bi401679y 24713062 [OpenAIRE] [PubMed] [DOI]
Brand E. J.Zhao Z. (2017). Cannabis in Chinese medicine: are some traditional indications referenced in ancient literature related to cannabinoids? Front. Pharmacol. 8:108. 10.3389/fphar.2017.00108 28344554 [OpenAIRE] [PubMed] [DOI]
Cast A.Valanejad L.Wright M.Nguyen P.Gupta A.Zhu L. (2017). C/EBPα-dependent pre-neoplastic tumor foci are the origin of hepatocellular carcinoma and aggressive pediatric liver cancer. Hepatology 10.1002/hep.29677 [Epub ahead of print]. 29159818 [OpenAIRE] [PubMed] [DOI]
Chapman A. M.McNaughton B. R. (2015). Synthetic proteins potently and selectively bind the oncoprotein gankyrin, modulate its interaction with S6 ATPase, and suppress gankyrin/MDM2-dependent ubiquitination of p53. ACS Chem. Biol. 10 1880–1886. 10.1021/acschembio.5b00201 25955581 [OpenAIRE] [PubMed] [DOI]
Chapman A. M.Rogers B. E.McNaughton B. R. (2014). Characterization of the binding interaction between the oncoprotein gankyrin and a grafted S6 ATPase. Biochemistry 53 6857–6859. 10.1021/bi5012354 25343477 [OpenAIRE] [PubMed] [DOI]
Chattopadhyay A.O’Connor C. J.Zhang F.Galvagnion C.Galloway W. R.Tan Y. S. (2016). Discovery of a small-molecule binder of the oncoprotein gankyrin that modulates gankyrin activity in the cell. Sci. Rep. 6:23732. 10.1038/srep23732 27046077 [OpenAIRE] [PubMed] [DOI]
Crowe D. L.Chandraratna R. A. (2004). A retinoid X receptor (RXR)-selective retinoid reveals that RXR-α is potentially a therapeutic target in breast cancer cell lines, and that it potentiates antiproliferative and apoptotic responses to peroxisome proliferator-activated receptor ligands. Breast Cancer Res. 6 R546–R555. 10.1186/bcr913 15318936 [OpenAIRE] [PubMed] [DOI]
Fleischer T.Su Y. C.Lin S. J. (2017). How do government regulations influence the ability to practice Chinese herbal medicine in western countries. J. Ethnopharmacol. 196 104–109. 10.1016/j.jep.2016.11.047 27915077 [OpenAIRE] [PubMed] [DOI]
Fritsche K. (2006). Fatty acids as modulators of the immune response. Annu. Rev. Nutr. 26 45–73. 10.1146/annurev.nutr.25.050304.092610 16848700 [OpenAIRE] [PubMed] [DOI]
Fu J.Chen Y.Cao J.Luo T.Qian Y. W.Yang W. (2011). p28GANK overexpression accelerates hepatocellular carcinoma invasiveness and metastasis via phosphoinositol 3-kinase/AKT/hypoxia-inducible factor-1α pathways. Hepatology 53 181–192. 10.1002/hep.24015 21254169 [OpenAIRE] [PubMed] [DOI]
Georgiadi A.Kersten S. (2012). Mechanisms of gene regulation by fatty acids. Adv. Nutr. 3 127–134. 10.3945/an.111.001602 22516720 [OpenAIRE] [PubMed] [DOI]
Gu Y.Sun X. X.Ye J. M.He L.Yan S. S.Zhang H. H. (2012). Arctigenin alleviates ER stress via activating AMPK. Acta Pharmacol. Sin. 33 941–952. 10.1038/aps.2012.60 22705729 [OpenAIRE] [PubMed] [DOI]
Gupta R. A.Tan J.Krause W. F.Geraci M. W.Willson T. M.Dey S. K. (2000). Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer. Proc. Natl. Acad. Sci. U.S.A. 97 13275–13280. 10.1073/pnas.97.24.13275 11087869 [OpenAIRE] [PubMed] [DOI]
Han L.Wang P.Sun Y.Liu S.Dai J. (2017). Anti-melanoma activities of haspin inhibitor CHR-6494 deployed as a single agent or in a synergistic combination with MEK inhibitor. J. Cancer 8 2933–2943. 10.7150/jca.20319 28928884 [OpenAIRE] [PubMed] [DOI]